TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)
Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –
TG Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
TG Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $136.45M, up 58.9% year over year. For fiscal 2025 it was $123.38M, up 193.8% from the year before. The highest annual figure on record is $123.38M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $123.38M | +193.8% |
| FY2024 | Dec 31, 2024 | $42.00M | +101.5% |
| FY2023 | Dec 31, 2023 | $20.84M | – |
| FY2022 | Dec 31, 2022 | -$218.01M | – |
| FY2021 | Dec 31, 2021 | -$344.49M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $21.73M | -37.7% |
| Q1 FY2026 | Mar 31, 2026 | $34.83M | +303.6% |
| Q4 FY2025 | Dec 31, 2025 | $50.52M | +68.6% |
| Q3 FY2025 | Sep 30, 2025 | $29.38M | +136.1% |
| Q2 FY2025 | Jun 30, 2025 | $34.86M | +294.5% |
| Q1 FY2025 | Mar 31, 2025 | $8.63M | – |
| Q4 FY2024 | Dec 31, 2024 | $29.96M | – |
| Q3 FY2024 | Sep 30, 2024 | $12.45M | -89.2% |
| Q2 FY2024 | Jun 30, 2024 | $8.84M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.24M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.45M | – |
| Q3 FY2023 | Sep 30, 2023 | $114.86M | – |
| Q2 FY2023 | Jun 30, 2023 | -$44.64M | – |
| Q1 FY2023 | Mar 31, 2023 | -$36.92M | – |
See a number that looks wrong?